Tumor Markers in Pancreatic Cancer: 2013

  • Urvi Ajay Shah Tufts Medical Center. Boston, MA, USA
  • Muhammad Wasif Saif Tufts Medical Center. Boston, MA, USA
Keywords: CA-19-9 Antigen, Pancreatic Neoplasms, Prognosis

Abstract

Amongst the tumor markers for pancreatic cancer CA 19-9 is being used most widely and newer clinically useful applications of this tumor marker are being researched. We will discuss four abstracts presented at the American Society of Clinical Oncology (ASCO) Annual Meeting which contribute to expanding the application of CA 19-9 measurement (Abstracts #4042, #4058, #e15082, #e15146).

Image: Sequence of therapeutic interventions and subsequent mean CA19-9 measurements.

 

Downloads

Download data is not yet available.

Author Biographies

Urvi Ajay Shah, Tufts Medical Center. Boston, MA, USA
Internal Medicine Resident, Department of Internal Medicine, Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USA
Muhammad Wasif Saif, Tufts Medical Center. Boston, MA, USA

Director, Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine and

Tufts Cancer Center

800 Washington Street, Boston, MA 02111, USA

References

Bilimoria, K.Y., et al., Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer, 2007. 110(4): p. 738-44.

American Cancer Society. Cancer Facts & Figures 2013. Atlanta: American Cancer Society; 2013

Bussom, S. and M.W. Saif, Methods and rationale for the early detection of pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. JOP : Journal of the pancreas, 2010. 11(2): p. 128-30.

Koprowski, H., et al., Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic cell genetics, 1979. 5(6): p. 957-71.

Tempero, M.A., et al., Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer research, 1987. 47(20): p. 5501-3.

Ballehaninna, U.K. and R.S. Chamberlain, The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. Journal of gastrointestinal oncology, 2012. 3(2): p. 105-19.

Sugiura, T., et al., Serum CA 19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2012. 16(5): p. 977-85.

Lee, K.J., et al., Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma. Yonsei medical journal, 2013. 54(3): p. 643-9.

Humphris, J.L., et al., The prognostic and predictive value of serum CA 19.9 in pancreatic cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2012. 23(7): p. 1713-22.

Haas, M., et al., Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. Journal of cancer research and clinical oncology, 2013. 139(4): p. 681-9.

Nakai, Y., et al., A retrospective analysis of early CA 19-9 progression in salvage chemotherapy for refractory pancreatic cancer. Journal of Clinical Oncology 31, 2013 (suppl; abstr e15146)

Chiorean, E. G., et al., CA 19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC.) Journal of Clinical Oncology 31, 2013 (suppl; abstr 4058)

Tsai S., et al, Association of decline in serum CA 19-9 after neoadjuvant therapy with improved survival among borderline resectable pancreatic cancer patients. Journal of Clinical Oncology 31, 2013 (suppl; abstr e15082)

Heymach J., et al, Circulating cytokines and angiogenic factors (CAF) as markers of clinical response in the study of trametinib (T) plus gemcitabine (G) versus placebo (P) plus gemcitabine for patients (pts) with untreated metastatic adenocarcinoma of the pancreas (MEK113487). Journal of Clinical Oncology 31, 2013 (suppl; abstr 4042)

Sequence of therapeutic interventions and subsequent mean CA19-9 measurements
Published
2013-07-10
How to Cite
Shah, U., & Saif, M. (2013). Tumor Markers in Pancreatic Cancer: 2013. JOP. Journal of the Pancreas, 14(4), 318-321. https://doi.org/10.6092/1590-8577/1653
Section
Highlights from the “2013 ASCO Annual Meeting”. Chicago, IL, USA. May 31 - June 4, 2013

Most read articles by the same author(s)

1 2 > >>